SAB Biotherapeutics Stock (NASDAQ:SABS)

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing immunotherapies built upon human antibodies. The company leverages sophisticated genetic engineering and antibody research to cultivate specialized transchromosomic bovine herds. These unique animals are engineered to generate fully human antibodies, which are then directed against a variety of specific ailments. This broad scope includes infectious diseases such as COVID-19 and influenza, various immune and autoimmune conditions like type 1 diabetes, and potential applications in organ transplantation and cancer treatment. Central to their strategy is the proprietary DiversitAb immunotherapy platform, which yields wholly human polyclonal antibodies, thereby circumventing the need for human donors. Key assets in their clinical pipeline feature SAB-185, a fully human polyclonal antibody therapeutic currently undergoing Phase III trials for COVID-19, and SAB-176, another fully human polyclonal antibody in development for the prevention or treatment of severe influenza. Additionally, their preclinical portfolio contains SAB-142, intended for autoimmune disorders such as type 1 diabetes and for managing organ transplant induction/rejection. Established in 2014, SAB Biotherapeutics is based in Sioux Falls, South Dakota.